Truempah Tablet 10 mg (Empagliflozin)

Adult dose

Type 2 diabetes: 10 mg once daily as monotherapy or in combination with other hypoglycemic agents. If tolerance is good and additional blood glucose control is needed, the dose may be increased to 25 mg once daily. Chronic heart failure: 10 mg once daily. Chronic kidney disease: 10 mg once daily, to be combined with other standard treatment for chronic kidney disease. When taking, swallow the tablet whole regardless of meals.

This drug should not be used by individuals who are allergic to the active substance or constituents, type 1 diabetes patients, those with diabetic ketoacidosis, and individuals with genetic issues such as lactose intolerance or galactose intolerance. Patients with impaired kidney function should have their renal function regularly monitored while using this drug, and it is not recommended for patients with severe renal impairment or those on dialysis. When taken with medications such as insulin or sulfonylureas, there is a risk of hypoglycemia, so blood sugar levels should be closely monitored during treatment and insulin dosage adjusted as necessary. During treatment, side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, and reduced fluid volume may occur, and if symptoms develop, medical consultation should be sought immediately. Particularly in diabetic patients, rare life-threatening ketoacidosis may occur, so if symptoms such as vomiting, abdominal pain, or difficulty breathing develop, immediate treatment should be sought, and these symptoms should be closely monitored during treatment. Elderly patients or those at risk of fluid volume loss should be cautious of dehydration and hypotension, and may need to temporarily discontinue this drug if necessary. This drug can cause liver damage, so any symptoms indicating liver dysfunction should be reported to a healthcare provider immediately. Attention is needed while driving or operating machinery due to the risk of hypoglycemia, especially when taken with insulin or sulfonylureas. Women who are pregnant or planning to become pregnant should avoid using this drug, and breastfeeding should be discontinued during treatment. Children and adolescents (under 18 years) should not use this drug, as its safety and efficacy have not been established.

Serious side effects

Urticaria, angioedema, ketoacidosis, urosepsis, pyelonephritis, perineal necrosis, liver damage, acute kidney injury, severe rash with fever, blisters, skin peeling, oral/ocular mucosal pain, difficulty breathing or shortness of breath, asthma attacks, respiratory distress accompanied by cough and fever, jaundice (yellowing of skin or eyes), generalized extreme fatigue, sudden and severe headache, thunderclap headache, seizures, confusion, visual disturbances

Mild side effects

• Hypoglycemia
• constipation
• itching
• rash
• increased serum lipids
• increased serum creatinine
• decreased glomerular filtration rate
• increased hematocrit
• vulvovaginitis
• balanitis

This drug should be stored in a tightly sealed container to prevent air or moisture ingress. It is recommended to store at room temperature, specifically between 1°C and 30°C, to maintain its efficacy and ensure safe use.

Appearance

Pale yellow, round film-coated tablet

Package unit

Domestic - 30 tablets/PTP [(10 tablets/PTP × 3)]